CRDF

Cardiff Oncology, Inc. Common Stock

1.28

USD

-0.03

-2.29%

Sep 24, 15:55 UTC -4

Closed

Pre-Market

1.29

+0.01

+1.17%

Cardiff Oncology, Inc. Common Stock Profile

About

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.

Info & Links

CEO

Mani Mohindru

Headquarters

11055 FLINTKOTE AVENUE
SAN DIEGO, CA 92121, UNITED STATES

Auditor

BDO USA, P.C.

Share holders

Employees

Cardiff Oncology, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

100.74M

Enterprise Value

91.55M

Enterprise Value/EBITDA(ttm)

-2.15

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

203.68

Price to Book(mrq)

3.43

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-7885.43%

Profit Margin(ttm)

-12841.54%

Return on Equity(ttm)

-103.10%

Return on Invested Capital(ttm)

-109.34%

Return on Assets(ttm)

-75.52%

Income Statement

Revenue(ttm)

508.00K

Revenue Per Share(ttm)

0.01

Gross Profit(ttm)

508.00K

EBITDA(ttm)³

-42.48M

Net Income Available to Common(ttm)

-40.08M

Diluted EPS(ttm)

-0.60

Share Statistics

Beta (5Y Monthly)

1.46

52-Week Change

-38.16%

S&P 500 52-Week Change

19.38%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

77.80M

Dividend Yield

0.00%

Float⁴

70.95M

% Held by Insiders

8.80%

% Held by Institutions

16.29%

Balance Sheet

Total Cash(mrq)

34.52M

Total Cash Per Share(mrq)

0.44

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.30%

Quick Ratio(mrq)

3.30%

Book Value Per Share(mrq)

0.39

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.35

Free Cash Flow(ytd)

-24.10M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.